Ionis Pharmaceuticals (BMV:IONS *) - Hisse Senedi Fiyatı, Haberler ve Analizler

IONS * Stoklara Genel Bakış

Ionis Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde RNA-hedefli terapötikleri keşfeder ve geliştirir. Daha fazla detay

IONS * temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 21.86% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Ionis Pharmaceuticals, Inc. Rakipler

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$37.4b

Hualan Biological Engineering

SZSE:002007

CN¥30.5b

Abcam

NasdaqGS:ABCM

US$5.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Ionis Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$720.55
52 Haftanın En Yüksek Seviyesi	US$900.00
52 Haftanın En Düşük Seviyesi	US$720.55
Beta	0.39
11 Aylık Değişim	-5.81%
3 Aylık Değişim	-19.94%
1 Yıllık Değişim	n/a
33 Yıllık Değişim	18.70%
5 Yıllık Değişim	-32.55%
Halka arzdan bu yana değişim	-46.80%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IONS *	MX Biotechs	MX Pazar
7D	-7.9%	0%	0%
1Y	n/a	0%	0%

Getiri vs. Endüstri: IONS * un MX Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: IONS * un MX Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is IONS *'s price volatile compared to industry and market?
IONS * volatility
IONS * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

İstikrarlı Hisse Senedi Fiyatı: IONS * hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IONS * 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1989	927	Brett Monia	www.ionispharma.com

Ionis Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde RNA-hedefli terapötikleri keşfeder ve geliştirir. Şirket, pediatrik ve yetişkin hastalarda spinal musküler atrofi (SMA) için SPINRAZA; yetişkinlerde kalıtsal transtiretin amiloidozunun neden olduğu polinöropatinin tedavisi için bir antisens enjeksiyon olan TEGSEDI; ve ailesel şilomikronemi sendromu (FCS) ve ailesel kısmi lipodistrofi tedavisi için bir antisens ilaç olan WAYLIVRA'yı sunmaktadır. Ayrıca, tüm ATTR tiplerini tedavi etmek için aylık kendi kendine uygulanan subkutan enjeksiyon olarak Eplontersen; FCS ve şiddetli hipertrigliseridemi (SHTG) hastaları için Olezarsen; kalıtsal anjiyoödem hastaları için Donidalorsen dahil olmak üzere faz 3 çalışmasında olan çeşitli endikasyonlar için ilaçlar geliştirmektedir; Amiyotrofik lateral skleroz hastaları için ION363; süperoksit dismutaz 1 üretimini inhibe etmek için Tofersen; yerleşik kardiyovasküler hastalığı ve yüksek lipoprotein (a) olan hastalar için Pelacarsen; ve hepatit B virüsü ile ilişkili viral proteinlerin üretimini inhibe etmek için Bepirovirsen.

Ionis Pharmaceuticals, Inc. Temel Bilgiler Özeti

Ionis Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IONS * temel i̇stati̇sti̇kler
Piyasa değeri	Mex$109.98b
Kazançlar(TTM)	-Mex$7.35b
Gelir(TTM)	Mex$16.45b

6.7x

P/S Oranı

-15.0x

F/K Oranı

IONS * aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IONS * gelir tablosu (TTM)
Gelir	US$803.07m
Gelir Maliyeti	US$917.98m
Brüt Kâr	-US$114.91m
Diğer Giderler	US$243.90m
Kazançlar	-US$358.81m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.27
Brüt Marj	-14.31%
Net Kâr Marjı	-44.68%
Borç/Özkaynak Oranı	275.7%

IONS * uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IONS * Stoklara Genel Bakış

Ödüller

Risk Analizi

Ionis Pharmaceuticals, Inc. Rakipler

BMV:LAB B

Mex$24.9b

SEHK:6990

HK$37.4b

SZSE:002007

CN¥30.5b

NasdaqGS:ABCM

US$5.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Insufficient new directors

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Recent updates

Insufficient new directors

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Insufficient new directors

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Insufficient new directors

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)